CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 144 enrolled
Drug / intervention
Ciprofloxacin +1 moredrug
Likely dose
Ciprofloxacin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02300220
NCT02300220Phase 3Completed
CompareCT.gov

Targeted Retreatment of Incompletely Recovered COPD Exacerbations With Ciprofloxacin: a Double-blind, Randomised, Placebo-controlled, Multicentre Phase III Trial

Imperial College London·interventional·Posted Nov 24, 2014·Updated Mar 8, 2021

In Brief

A Phase 3 clinical trial evaluating Ciprofloxacin and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 144 participants across 4 sites.

Detailed Summary

This study investigates the effects of targeted re-treatment of patients who do not recover from an exacerbation of COPD. Half of the patients will receive ciprofloxacin while the other half will receive a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 24, 2014
Enrollment StartMay 5, 2014
Primary CompletionJan 22, 2019
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 11.6 years ago

Interventions

Ciprofloxacindrug

500 mg, twice daily for 1 week (oral)

Placebodrug

One capsule, twice daily for 1 week